EUROPEAN PHARMACOPOEIA

SEVENTH EDITION

Volume 1

Published in accordance with the Convention on the Elaboration of a European Pharmacopoeia (European Treaty Series No. 50)

European Directorate for the \mathcal{A} Quality of Medicines & HealthCare

Council of Europe Strasbourg



The European Pharmacopoeia is published by the Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM).

© Council of Europe, 67075 Strasbourg Cedex, France - 2010

All rights reserved. Apart from any fair dealing for the purposes of research or private study, this publication may not be reproduced, stored or transmitted in any form or by any means without the prior permission in writing of the publisher.

ISBN: 978-92-871-6700-2

DOCKE

Δ

RM

the animal from loss of body heat and maintain it so that the rectal temperature remains within physiological limits. Introduce a cannula into the trachea. Insert a cannula filled with a heparinised 9 g/L solution of sodium chloride into the common carotid artery and connect it to a device capable of giving a continuous record of the blood pressure. Insert into the femoral vein another cannula, filled with a heparinised 9 g/L solution of sodium chloride, through which can be injected the solutions of histamine and of the substance to be examined. Determine the sensitivity of the animal to histamine by injecting intravenously at regular intervals, doses of histamine solution R corresponding to 0.1 µg and 0.15 µg of histamine base per kilogram of body mass. Repeat the lower dose at least 3 times. Administer the second and subsequent injections not less than 1 min after the blood pressure has returned to the level it was at immediately before the previous injection. The animal is used for the test only if a readily discernible decrease in blood pressure that is constant for the lower dose is obtained and if the higher dose causes greater responses. Dissolve the substance to be examined in sufficient of a 9 g/L solution of sodium chloride or other prescribed solvent, to give the prescribed concentration. Inject intravenously per kilogram of body mass 1.0 mL of histamine solution R, followed by 2 successive injections of the prescribed amount of the solution to be examined and, finally, 1.0 mL of histamine solution R. The second, third and fourth injections are given not less than 1 min after the blood pressure has returned to the level it was at immediately before the preceding injection. Repeat this series of injections twice and conclude the test by giving 1.5 mL of histamine solution R per kilogram of body mass.

If the response to 1.5 mL of *histamine solution* R per kilogram of body mass is not greater than that to 1.0 mL the test is invalid. The substance to be examined fails the test if the mean of the series of responses to the substance is greater than the mean of the responses to 1.0 mL of *histamine solution* R per kilogram of body mass or if any one dose of the substance causes a greater depressor response than the concluding dose of the histamine solution. The test animal must not be used in another test for depressor substances if the second criterion applies or if the response to the high dose of histamine given after the administration of the substance to be examined is less than the mean response to the low doses of histamine previously injected.

07/2010:20612

2.6.12. MICROBIOLOGICAL EXAMINATION OF NON-STERILE PRODUCTS: MICROBIAL ENUMERATION TESTS⁽²⁾

1. INTRODUCTION

DOCKE

The tests described hereafter will allow quantitative enumeration of mesophilic bacteria and fungi that may grow under aerobic conditions.

The tests are designed primarily to determine whether a substance or preparation complies with an established specification for microbiological quality. When used for such purposes follow the instructions given below, including the number of samples to be taken, and interpret the results as stated below.

The methods are not applicable to products containing viable micro-organisms as active ingredients.

Alternative microbiological procedures, including automated methods, may be used, provided that their equivalence to the Pharmacopoeia method has been demonstrated.

2. GENERAL PROCEDURES

Carry out the determination under conditions designed to avoid extrinsic microbial contamination of the product to be examined. The precautions taken to avoid contamination must be such that they do not affect any micro-organisms that are to be revealed in the test.

If the product to be examined has antimicrobial activity, this is insofar as possible removed or neutralised. If inactivators are used for this purpose, their efficacy and their absence of toxicity for micro-organisms must be demonstrated.

If surface-active substances are used for sample preparation, their absence of toxicity for micro-organisms and their compatibility with inactivators used must be demonstrated.

3. ENUMERATION METHODS

Use the membrane filtration method or the plate-count methods, as prescribed. The most-probable-number (MPN) method is generally the least accurate method for microbial counts, however, for certain product groups with a very low bioburden, it may be the most appropriate method.

The choice of method is based on factors such as the nature of the product and the required limit of micro-organisms. The chosen method must allow testing of a sufficient sample size to judge compliance with the specification. The suitability of the method chosen must be established.

4. GROWTH PROMOTION TEST, SUITABILITY OF THE COUNTING METHOD AND NEGATIVE CONTROLS

4-1. GENERAL CONSIDERATIONS

The ability of the test to detect micro-organisms in the presence of product to be tested must be established.

Suitability must be confirmed if a change in testing performance, or the product, which may affect the outcome of the test is introduced.

4-2. PREPARATION OF TEST STRAINS

Use standardised stable suspensions of test strains or prepare them as stated below. Seed lot culture maintenance techniques (seed-lot systems) are used so that the viable micro-organisms used for inoculation are not more than 5 passages removed from the original master seed-lot. Grow each of the bacterial and fungal test strains separately as described in Table 2.6.12.1.

Use buffered sodium chloride-peptone solution pH 7.0 or phosphate buffer solution pH 7.2 to make test suspensions; to suspend *A. brasiliensis* spores, 0.05 per cent of polysorbate 80 may be added to the buffer. Use the suspensions within 2 h or within 24 h if stored at 2-8 °C. As an alternative to preparing and then diluting a fresh suspension of vegetative cells of *A. brasiliensis* or *B. subtilis*, a stable spore suspension is prepared and then an appropriate volume of the spore suspension is used for test inoculation. The stable spore suspension may be maintained at 2-8 °C for a validated period of time.

4-3. NEGATIVE CONTROL

To verify testing conditions, a negative control is performed using the chosen diluent in place of the test preparation. There must be no growth of micro-organisms. A negative control is also performed when testing the products as described in section 5. A failed negative control requires an investigation.

4-4. GROWTH PROMOTION OF THE MEDIA

Test each batch of ready-prepared medium and each batch of medium, prepared either from dehydrated medium or from the ingredients described.

Inoculate portions/plates of casein soya bean digest broth and casein soya bean digest agar with a small number (not more than 100 CFU) of the micro-organisms indicated in Table 2.6.12.-1, using a separate portion/plate of medium for each. Inoculate plates of Sabouraud-dextrose agar with a small number (not

(1) This chapter has undergone pharmacopoeial harmonisation. See chapter 5.8. Pharmacopoeial harmonisation.

General Notices (1) apply to all monographs and other texts

163

Find authenticated court documents without watermarks at docketalarm.com.

| Micro-organism | Preparation of test strain | Growth promotion | | Suitability of counting method in the presence of the product | |
|--|---|---|---|---|---|
| | | Total aerobic microbial count | Total yeasts and moulds count | Total aerobic microbial count | Total yeasts and moulds count |
| Staphylococcus aureus such as: ATCC 6538 NCIMB 9518 CIP 4.83 NBRC 13276 | Casein soya bean digest agar or casein soya bean digest broth 30-35 °C 18-24 h | Casein soya bean digest agar and casein soya bean digest broth ≤ 100 CFU 30-35 °C ≤ 3 days | | Casein soya bean digest agar/MPN casein soya bean digest broth ≤ 100 CFU 30-35 °C ≤ 3 days | - |
| Pseudomonas aeruginosa such as: ATCC 9027 NCIMB 8626 CIP 82.118 NBRC 13275 | Casein soya bean digest agar or casein soya bean digest broth 30.35 °C 18-24 h | Casein soya bean digest agar and casein soya bean digest broth ≤ 100 CFU 30.35 °C ≤ 3 days | - | Casein soya bean digest agar/MPN casein soya bean digest broth ≤ 100 CPU 30-35 °C ≤ 3 days | - |
| Bacillus subtilis such as: ATCC 6633 NCIMB 8054 CIP 52.62 NBRC 3134 | Casein soya bean digest agar or casein soya bean digest broth 30-35 °C 18-24 h | Casein soya bean digest agar and casein soya bean digest broth ≤ 100 CFU 30-35 °C ≤ 3 days | - | Casein soya bean digest agar/MPN casein soya bean digest broth ≤ 100 CFU 30-35 °C ≤ 3 days | - |
| Candida albicans such as: ATCC 10231 NCPF 3179 IP 48.72 NBRC 1594 | Sabouraud-dextrose agar or Sabouraud- dextrose broth 20-25 °C 2-3 days | Casein soya bean digest agar ≤ 100 CFU 30-35 °C ≤ 5 days | Sabouraud-dextrose agar ≤ 100 CFU 20-25 °C ≤ 5 days | Casein soya bean digest agar ≤ 100 CFU 30-35 °C ≤ 5 days MPN: not applicable | Sabouraud-dextrose agar ≤ 100 CFU 20-25 °C ≤ 5 days |
| Aspergillus brasiliensis such as: ATCC 16404 IMI 149007 IP 1431.83 NBRC 9455 | Sabouraud-dextrose agar or potato-dextrose agar 20-25 °C 5-7 days, or until good sporulation is achieved | Casein soya bean digest agar ≤ 100 CFU 30-35 °C ≤ 5 days | Sabouraud-dextrose agar ≤ 100 CFU 20:25 °C ≤ 5 days | Casein soya bean digest agar ≤ 100 CFU 30-35 °C ≤ 5 days MPN: not applicable | Sabouraud-dextrose agar ≤ 100 CFU 20-25 °C ≤ 5 days |

more than 100 CFU) of the micro-organisms indicated in Table 2.6.12.-1, using a separate plate of medium for each. Incubate in the conditions described in Table 2.6.12.-1.

For solid media, growth obtained must not differ by a factor greater than 2 from the calculated value for a standardised inoculum. For a freshly prepared inoculum, growth of the micro-organisms comparable to that previously obtained with a previously tested and approved batch of medium occurs. Liquid media are suitable if clearly visible growth of the micro-organisms comparable to that previously obtained with a previously tested and approved batch of medium occurs.

4-5. SUITABILITY OF THE COUNTING METHOD IN THE PRESENCE OF PRODUCT

4-5-1. **Preparation of the sample**. The method for sample preparation depends upon the physical characteristics of the product to be tested. If none of the procedures described below can be demonstrated to be satisfactory, an alternative procedure must be developed.

Water-soluble products. Dissolve or dilute (usually a 1 in 10 dilution is prepared) the product to be examined in buffered sodium chloride-peptone solution pH 7.0, phosphate buffer solution pH 7.2 or casein soya bean digest broth. If necessary, adjust to pH 6-8. Further dilutions, where necessary, are prepared with the same diluent.

Non-fatty products insoluble in water. Suspend the product to be examined (usually a 1 in 10 dilution is prepared) in buffered sodium chloride-peptone solution pH 7.0, phosphate buffer solution pH 7.2 or casein soya bean digest broth. A surface active agent such as 1 g/L of polysorbate 80 may be added to assist the suspension of poorly wettable substances. If necessary, adjust to pH 6-8. Further dilutions, where necessary, are prepared with the same diluent.

Fatty products. Dissolve in isopropyl myristate, sterilised by filtration or mix the product to be examined with the minimum necessary quantity of sterile polysorbate 80 or another

non-inhibitory sterile surface-active agent, heated if necessary to not more than 40 °C, or in exceptional cases to not more than 45 °C. Mix carefully and if necessary maintain the temperature in a water-bath. Add sufficient of the pre-warmed chosen diluent to make a 1 in 10 dilution of the original product. Mix carefully whilst maintaining the temperature for the shortest time necessary for the formation of an emulsion. Further serial tenfold dilutions may be prepared using the chosen diluent containing a suitable concentration of sterile polysorbate 80 or another non-inhibitory sterile surface-active agent.

Fluids or solids in aerosol form. Aseptically transfer the product into a membrane filter apparatus or a sterile container for further sampling. Use either the total contents or a defined number of metered doses from each of the containers tested.

Transdermal patches. Remove the protective cover sheets ('release liners') of the transdermal patches and place them, adhesive side upwards, on sterile glass or plastic trays. Cover the adhesive surface with a sterile porous material, for example sterile gauze, to prevent the patches from sticking together, and transfer the patches to a suitable volume of the chosen diluent containing inactivators such as polysorbate 80 and/or lecithin. Shake the preparation vigorously for at least 30 min.

4-5-2. **Inoculation and dilution**. Add to the sample prepared as described above (4-5-1) and to a control (with no test material included) a sufficient volume of the microbial suspension to obtain an inoculum of not more than 100 CFU. The volume of the suspension of the inoculum should not exceed 1 per cent of the volume of diluted product.

To demonstrate acceptable microbial recovery from the product, the lowest possible dilution factor of the prepared sample must be used for the test. Where this is not possible due to antimicrobial activity or poor solubility, further appropriate protocols must be developed. If inhibition of growth by the sample cannot otherwise be avoided, the aliquot of the microbial

164

See the information section on general monographs (cover pages)

suspension may be added after neutralisation, dilution or filtration.

4-5-3. Neutralisation/removal of antimicrobial activity. The number of micro-organisms recovered from the prepared sample diluted as described in 4-5-2 and incubated following the procedure described in 4-5-4, is compared to the number of micro-organisms recovered from the control preparation.

If growth is inhibited (reduction by a factor greater than 2), then modify the procedure for the particular enumeration test to ensure the validity of the results. Modification of the procedure may include, for example, (1) an increase in the volume of the diluent or culture medium, (2) incorporation of specific or general neutralising agents into the diluent, (3) membrane filtration, or (4) a combination of the above measures.

Neutralising agents. Neutralising agents may be used to neutralise the activity of antimicrobial agents (Table 2.6.12.-2). They may be added to the chosen diluent or the medium preferably before sterilisation. If used, their efficacy and their absence of toxicity for micro-organisms must be demonstrated by carrying out a blank with neutraliser and without product.

Table 2.6.12.-2. – Common neutralising agents for interfering substances

| Interfering substance | Potential neutralising method | |
|---|--|--|
| Glutaraldehyde, mercurials | Sodium hydrogensulfite (sodium bisulfite) | |
| Phenolics, alcohol, aldehydes, sorbate | Dilution | |
| Aldehydes | Glycine | |
| Quaternary Ammonium Compounds (QACs), parahydroxybenzoates (parabens), bis-biguanides | Lecithin | |
| QACs, iodine, parabens | Polysorbate | |
| Mercurials | Thioglycollate | |
| Mercurials, halogens, aldehydes | Thiosulfate | |
| EDTA (edetate) | Mg ²⁺ or Ca ²⁺ ions | |

If no suitable neutralising method can be found, it can be assumed that the failure to isolate the inoculated organism is attributable to the microbicidal activity of the product. This information serves to indicate that the product is not likely to be contaminated with the given species of the micro-organism. However, it is possible that the product only inhibits some of the micro-organisms specified herein, but does not inhibit others not included amongst the test strains or for which the latter are not representative. Then, perform the test with the highest dilution factor compatible with microbial growth and the specific acceptance criterion.

4-5-4. **Recovery of micro-organism in the presence of product**. For each of the micro-organisms listed, separate tests are performed. Only micro-organisms of the added test strain are counted.

4-5-4-1. *Membrane filtration*. Use membrane filters having a nominal pore size not greater than 0.45 μ m. The type of filter material is chosen such that the bacteria-retaining efficiency is not affected by the components of the sample to be investigated. For each of the micro-organisms listed, one membrane filter is used.

Transfer a suitable amount of the sample prepared as described under 4-5-1 to 4-5-3 (preferably representing 1 g of the product, or less if large numbers of CFU are expected) to the membrane filter, filter immediately and rinse the membrane filter with an appropriate volume of diluent.

For the determination of total aerobic microbial count (TAMC), transfer the membrane filter to the surface of casein soya bean digest agar. For the determination of total combined yeasts/moulds count (TYMC), transfer the membrane to the surface of Sabouraud-dextrose agar. Incubate the plates as indicated in Table 2.6.12.-1. Perform the counting.

4-5-4-2. *Plate-count methods*. Perform plate-count methods at least in duplicate for each medium and use the mean count of the result.

4-5-4-2-1. Pour-plate method

For Petri dishes 9 cm in diameter, add to the dish 1 mL of the sample prepared as described under 4-5-1 to 4-5-3 and 15-20 mL of casein soya bean digest agar or Sabouraud-dextrose agar, both media being at not more than 45 °C. If larger Petri dishes are used, the amount of agar medium is increased accordingly. For each of the micro-organisms listed in Table 2.6.12.-1, at least 2 Petri dishes are used. Incubate the plates as indicated in Table 2.6.12.-1. Take the arithmetic mean of the counts per medium and calculate the number of CFU in the original inoculum.

4-5-4-2-2. Surface-spread method

For Petri dishes 9 cm in diameter, add 15-20 mL of casein soya bean digest agar or Sabouraud-dextrose agar at about 45 °C to each Petri dish and allow to solidify. If larger Petri dishes are used, the volume of the agar is increased accordingly. Dry the plates, for example in a laminar-air-flow cabinet or an incubator. For each of the micro-organisms listed in Table 2.6.12.-1, at least 2 Petri dishes are used. Spread a measured volume of not less than 0.1 mL of the sample prepared as described under 4-5-1 to 4-5-3 over the surface of the medium. Incubate and count as prescribed under 4-5-4-2-1.

4-5-4-3. *Most-probable-number (MPN) method.* The precision and accuracy of the MPN method is less than that of the membrane filtration method or the plate-count method. Unreliable results are obtained particularly for the enumeration of moulds. For these reasons the MPN method is reserved for the enumeration of TAMC in situations where no other method is available. If the use of the method is justified, proceed as follows.

Prepare a series of at least 3 serial tenfold dilutions of the product as described under 4-5-1 to 4-5-3. From each level of dilution, 3 aliquots of 1 g or 1 mL are used to inoculate 3 tubes with 9-10 mL of casein soya bean digest broth. If necessary, a surface-active agent such as polysorbate 80 or an inactivator of antimicrobial agents may be added to the medium. Thus, if 3 levels of dilution are prepared, 9 tubes are inoculated.

Incubate all tubes at 30-35 °C for not more than 3 days. If reading of the results is difficult or uncertain owing to the nature of the product to be examined, subculture in the same broth, or in casein soya bean digest agar, for 1-2 days at the same temperature and use these results. Determine the most probable number of micro-organisms per gram or millilitre of the product to be examined from Table 2.6.12.-3.

4-6. RESULTS AND INTERPRETATION

When verifying the suitability of the membrane filtration method or the plate-count method, a mean count of any of the test organisms not differing by a factor greater than 2 from the value of the control defined in 45-2 in the absence of the product must be obtained. When verifying the suitability of the MPN method the calculated value from the inoculum must be within 95 per cent confidence limits of the results obtained with the control.

If the above criteria cannot be met for one or more of the organisms tested with any of the described methods, the method and test conditions that come closest to the criteria are used to test the product.

5. TESTING OF PRODUCTS

5-1. AMOUNT USED FOR THE TEST

Unless otherwise prescribed, use 10 g or 10 mL of the product to be examined taken with the precautions referred to above. For fluids or solids in aerosol form, sample 10 containers. For transdermal patches, sample 10 patches.

General Notices (1) apply to all monographs and other texts

DOCKE

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.